

REMARKS/ARGUMENTS

Claims 21-48 are active. Claims 1-20 and 31-42 have been withdrawn from consideration. The claims have been amended for clarity and to conform with preferred U.S. practice, e.g., by eliminating multiple dependent claims. New Claims 43 and 44-48 find support in the original claims and on pages 12-15 of the specification. No new matter has been added.

Restriction/Election

The Applicants previously elected with traverse Group IV, claims 21-30. This requirement has been made FINAL. The Applicants respectfully request that the claims of the nonelected group(s) which depend from or otherwise include all the limitations of an allowed elected claim, be rejoined upon an indication of allowability for the elected claim, see MPEP 821.04.

Objection—Claim 30

Claim 30 was objected to as being in improper multiple dependent form. This objection is now moot.

Rejection—35 U.S.C. §102

Claims 21¹-31 were rejected as being anticipated by Wadlinger et al., U.S. Re. 28,341. This rejection is moot in view of the amendments above. Wadlinger do not disclose an agent comprising the ingredients now recited by Claim 21. Rather, this reissued patent is directed to zeolite beta per se and catalytic compositions containing it, see abstract and col. 1.

¹ Claim 20 was withdrawn from consideration. Claims 21-30 correspond to elected Group IV.

Application No. 10/563,870
Reply to Office Action of March 19, 2007


Compositions are mentioned in cols. 7-8, but do not include the ingredients required by
Claim 21. Accordingly, this rejection may now be withdrawn.

Conclusion

In view of the remarks above and the amendments, the Applicants respectfully submit that this application is now in condition for allowance. An early notification of such is earnestly requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon


Thomas M. Cunningham, Ph.D.
Registration No. 45,394

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 06/04)